A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer

BACKGROUND: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes. 4DCT scans performed for routine treatment were retrospectively analyzed to establish the benefits of gating in stage III non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Gross tumor volumes (GTVs) were contoured in all 10 respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed using different planning target volumes (PTVs), namely: (i) PTV(routine), derived from a single GTV plus 'conventional' margins; (ii) PTV(all phases )incorporating all 3D mobility captured by the 4DCT; (iii) PTV(gating), incorporating residual 3D mobility in 3–4 phases at end-expiration. Mixed effect models were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs. RESULTS: Individual GTVs ranged from 41.5 – 235.0 cm(3). With patient-specific mobility data (PTV(all phases)), smaller PTVs were derived than when 'standard' conventional margins were used (p < 0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were 9.7% and 4.9%, respectively, for PTV(all phases )versus PTV(routine), and PTV(gating )versus PTV(all phases). The corresponding reductions in V(20 )were 9.8% and 7.0%, respectively. Dosimetric gains were smaller for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also reduced the risks of radiation-induced esophagitis. CONCLUSION: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the benefits are particularly evident for tumors of the middle and lower lobes